CD8+ CTLs are directly capable of killing tumour cells and positively affect prognosis in a broad range of tumour types, including breast cancer, ovarian cancer, head and neck cancer and lung cancer [24–27]. This evidence concerns the gene CD8A and ovarian cancer.